Study Shows MiniMed™ 780G System Achieves ADA Time-in-Range Goals

A new retrospective analysis has revealed that users of the MiniMed™ 780G insulin delivery system effectively met the American Diabetes Association (ADA) recommended time-in-range (TIR) goals, even during days when mealtime boluses were not administered. Published in Diabetes Care, this study utilized CareLink™ data to assess user performance, showing that the user cohort attained a remarkable 76.3% TIR on days when mealtime boluses were missed by implementing SmartGuard™ technology with optimal settings.

Understanding the Study's Context

The analysis primarily examined off-label user behavior, as the MiniMed™ 780G system's labeling necessitates users to announce meals while utilizing SmartGuard™ technology. Notably, deliberately omitting boluses is not an approved method and is discouraged. This study underscores the significance of proper system settings, particularly for users who occasionally forget or skip boluses.

The Burden of Mealtime Management

Mealtime management poses significant challenges for individuals with type 1 diabetes, often causing distress. This reflects the constant need for decision-making concerning insulin and carbohydrate calculations, resulting in increased mental load. A recent study in Diabetes Technology & Therapeutics indicated that pediatric patients employing automated insulin delivery (AID) systems missed an average of 2.2 boluses per day, with each additional missed bolus decreasing TIR by nearly 10%.

Key Findings from the MiniMed™ 780G Study

Dr. Jennifer McVean, Senior Medical Affairs Director at Medtronic Diabetes and the study's lead investigator, commented, “While labeling requires meal bolusing for all automated insulin delivery systems, including the MiniMed™ 780G system, missed boluses are a reality in real-world use. This analysis indicated that 71.2% of MiniMed™ 780G users achieved ADA-recommended TIR goals on days when boluses were missed.”

Study Design and Breakdown

The retrospective study analyzed CareLink user data from January 2, 2020, to March 31, 2025, involving 369,467 users of the MiniMed™ 780G insulin pump paired with a compatible Medtronic sensor. It specifically focused on users who had at least ten days without bolusing, totaling 54,553 participants. The research compared glycemic outcomes on missed bolus days, distinguishing between those who employed the recommended optimal settings (N=12,723) and those who did not (N=41,830). Notable results include:

• TIR: 76.3% for recommended optimal settings vs. 69.3% for others
• Mean Sensor Glucose: 149 mg/dL vs. 160 mg/dL
• Glucose Management Indicator: 6.9% vs. 7.1%
• 61%: of users with recommended settings met all three ADA glycemic targets during missed bolus days compared to 36.6% with other settings

Implications for Diabetes Care

Que Dallara, EVP and President of Medtronic Diabetes, stated, “These findings underscore the advanced capabilities of the MiniMed™ 780G system and its potential to ease the daily burden of diabetes care. Our aim is to empower individuals with technology that adapts to their lifestyles, even when circumstances don't unfold as anticipated.”

About Medtronic Diabetes

Medtronic Diabetes is dedicated to making diabetes management more predictable, providing advanced technology and continuous support tailored to individual needs. Having pioneered innovations in diabetes technology for over 40 years, Medtronic continues to lead the way in developing first-of-its-kind solutions including next-generation sensors and intelligent insulin delivery systems.

Contact Information

For further inquiries, please contact:

• Janet Cho, Global Communications: +1 (818) 403-7028
• Ryan Weispfenning, Investor Relations: +1 (763) 505-4626